Bohdana Klimuk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Bohdana Klimuk has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
L. A. Rybchenko
State Institution «National Research Center for Radiation Medicine of the National Academy of Medical Sciences of Ukraine», 53 Melnykova str., Kyiv, 04050, Ukraine
2 shared publications- Liubov M. Zakhartseva
Bogomolets National Medical University, Kyiv, Ukraine
2 shared publications - Oleksandr Shumeiko
O.O. Bogomolets National Medical University, Kyiv 01601, Ukraine
2 shared publications S. V. Klymenko
State Institution «National Research Center for Radiation Medicine of the National Academy of Medical Sciences of Ukraine», 53 Melnykova str., Kyiv, 04050, UkraineBogomolets National Medical University, 13, Tarasa Shevchenko Blvd, Kyiv, 01601, Ukraine
2 shared publications- Sergiy V. Klymenko
SHUPYK NATIONAL HEALTHCARE UNIVERSITY OF UKRAINE, KYIV, UKRAINE
2 shared publications - Anastasiia Samusieva
Department of Oncology, Shupyk National Healthcare University of Ukraine
1 shared publication
Latest Publications
- Open Access
- 22 June 2026
- Published by Publishing Company VIT-A-POL in Modern Gastroenterology
- No. 2,p. 16-21
Association between MMP9 gene polymorphism and diverticular disease of the colon in patients residing in the central region of Ukraine
Objective — to investigate the frequency of the –1562C > T (rs3918242) polymorphic variant of the matrix metalloproteinase-9 (MMP9) gene and to evaluate its association with disease course in patients with different clinical variants of diverticular disease. Materials and methods. The study included 133 patients, residents of the central region of Ukraine, who received inpatient treatment at Feofaniya Clinical Hospital (State Administration of Affairs of Ukraine) from June to December 2024. Among them, 97 patients had colonic diverticula: 27 with diverticulosis and 70 with symptomatic diverticular disease. The control group consisted of 36 individuals without diverticula. All participants underwent colonoscopy to confirm the presence or absence of diverticula. Genotyping of the –1562C > T (rs3918242) polymorphism of the MMP9 gene was performed using peripheral blood samples in both patients with diverticula and control subjects. Results. The genotype frequencies of the –1562C > T (rs3918242) polymorphism of the MMP9 gene in patients with diverticula and controls were as follows: CC — 75.3% vs 69.5% (p=0.49), CT — 23.7% vs 27.7% (p=0.63), and TT — 1.0% vs 2.8% (p=0.47), respectively. The genotype distribution conformed to Hardy–Weinberg equilibrium, and no statistically significant differences between the groups were found (χ2=0.28; p=0.59). The allele frequencies of the MMP9 gene (rs3918242) in patients with diverticula were: C — 87.1% and T — 12.9%; in the control group: C — 83.3% and T — 16.7% (p=0.43). All inheritance models demonstrated no association between the –1562C > T (rs3918242) polymorphism of the MMP9 gene and the development of diverticula. The T allele frequency was 15.7% in patients with symptomatic diverticular disease compared with 5.6% in patients with asymptomatic diverticulosis (p=0.043). Conclusions. The frequency of the –1562C > T (rs3918242) polymorphism of the MMP9 gene did not differ significantly between patients with colonic diverticula and controls, indicating no statistically significant association between this polymorphism of the MMP9 gene and the presence of diverticula. However, the T allele was significantly more frequent in patients with symptomatic diverticular disease compared with those with diverticulosis.
- 22 June 2026
- Published by Publishing Company VIT-A-POL in Modern Gastroenterology
- No. 2,p. 16-21
Open AccessAssociation between MMP9 gene polymorphism and diverticular disease of the colon in patients residing in the central region of Ukraine
Objective — to investigate the frequency of the –1562C > T (rs3918242) polymorphic variant of the matrix metalloproteinase-9 (MMP9) gene and to evaluate its association with disease course in patients with different clinical variants of diverticular disease. Materials and methods. The study included 133 patients, residents of the central region of Ukraine, who received inpatient treatment at Feofaniya Clinical Hospital (State Administration of Affairs of Ukraine) from June to December 2024. Among them, 97 patients had colonic diverticula: 27 with diverticulosis and 70 with symptomatic diverticular disease. The control group consisted of 36 individuals without diverticula. All participants underwent colonoscopy to confirm the presence or absence of diverticula. Genotyping of the –1562C > T (rs3918242) polymorphism of the MMP9 gene was performed using peripheral blood samples in both patients with diverticula and control subjects. Results. The genotype frequencies of the –1562C > T (rs3918242) polymorphism of the MMP9 gene in patients with diverticula and controls were as follows: CC — 75.3% vs 69.5% (p=0.49), CT — 23.7% vs 27.7% (p=0.63), and TT — 1.0% vs 2.8% (p=0.47), respectively. The genotype distribution conformed to Hardy–Weinberg equilibrium, and no statistically significant differences between the groups were found (χ2=0.28; p=0.59). The allele frequencies of the MMP9 gene (rs3918242) in patients with diverticula were: C — 87.1% and T — 12.9%; in the control group: C — 83.3% and T — 16.7% (p=0.43). All inheritance models demonstrated no association between the –1562C > T (rs3918242) polymorphism of the MMP9 gene and the development of diverticula. The T allele frequency was 15.7% in patients with symptomatic diverticular disease compared with 5.6% in patients with asymptomatic diverticulosis (p=0.043). Conclusions. The frequency of the –1562C > T (rs3918242) polymorphism of the MMP9 gene did not differ significantly between patients with colonic diverticula and controls, indicating no statistically significant association between this polymorphism of the MMP9 gene and the presence of diverticula. However, the T allele was significantly more frequent in patients with symptomatic diverticular disease compared with those with diverticulosis.
- Open Access
- 8 June 2023
- Published by National Academy of Sciences of Ukraine (Co. LTD Ukrinformnauka) (Publications) in Experimental Oncology
- Vol. 41 (1) , 53-56
Copy number alterations and copy-neutral loss of heterozygosity in Ukrainian patients with primary myelofibrosis
Summary. Aim: To examine frequencies and spectrum of genomic alterations in Ukrainian patients diagnosed with primary myelofibrosis (PMF). Materials and Methods: We enrolled 30 Ukrainian patients diagnosed with PMF who were previously tested for usual mutations in myeloproliferative neoplasms driver genes (JAK2, MPL and CALR). Genomic DNA samples were obtained from peripheral blood leukocytes of these patients. Copy number alterations and copy-neutral loss of heterozygosity (cnLOH) were assessed using a high-density CytoScan HD microarray platform. Statistical significance was evaluated by the Fisher exact test. Results: We identified frequent genomic alterations, but no significant difference in the rates of copy-number loss, copy-number gain, cnLOH, or multiple genomic alterations were found in the groups of PMF patients that were positive for one of the usual mutations in driver genes or negative for such mutations (33.3% and 55.6%, p = 0.4181, 19.0% and 11.1%, p = 1.0000, 61.9% and 44.4%, p = 0.4434, 33.3% and 55.6%, p = 0.4181, respectively). The most frequent alterations were cnLOH at 1p36-1p22, 9p24.3-9p13.3 and 11q12.3-11q25; copy number loss at 7q21-7q36.3 and 13q12.3-13q14.3. Copy number alterations and cnLOH commonly affected the EZH2, LAMB4, CBL, CUX1, ATM, RB1 and TP53 genes, in addition to JAK2, MPL and CALR. Conclusion: We demonstrated the spectrum of genomic alterations in the groups of the Ukrainian PMF patients with or without the usual mutations in the specific driver genes. We identified several potential genes, which may be involved in the myeloproliferative neoplasms development and their phenotype modification (EZH2, LAMB4, CBL, CUX1, ATM, RB1 and TP53).
- 8 June 2023
- Published by National Academy of Sciences of Ukraine (Co. LTD Ukrinformnauka) (Publications) in Experimental Oncology
- Vol. 41 (1) , 53-56
Open AccessCopy number alterations and copy-neutral loss of heterozygosity in Ukrainian patients with primary myelofibrosis
Summary. Aim: To examine frequencies and spectrum of genomic alterations in Ukrainian patients diagnosed with primary myelofibrosis (PMF). Materials and Methods: We enrolled 30 Ukrainian patients diagnosed with PMF who were previously tested for usual mutations in myeloproliferative neoplasms driver genes (JAK2, MPL and CALR). Genomic DNA samples were obtained from peripheral blood leukocytes of these patients. Copy number alterations and copy-neutral loss of heterozygosity (cnLOH) were assessed using a high-density CytoScan HD microarray platform. Statistical significance was evaluated by the Fisher exact test. Results: We identified frequent genomic alterations, but no significant difference in the rates of copy-number loss, copy-number gain, cnLOH, or multiple genomic alterations were found in the groups of PMF patients that were positive for one of the usual mutations in driver genes or negative for such mutations (33.3% and 55.6%, p = 0.4181, 19.0% and 11.1%, p = 1.0000, 61.9% and 44.4%, p = 0.4434, 33.3% and 55.6%, p = 0.4181, respectively). The most frequent alterations were cnLOH at 1p36-1p22, 9p24.3-9p13.3 and 11q12.3-11q25; copy number loss at 7q21-7q36.3 and 13q12.3-13q14.3. Copy number alterations and cnLOH commonly affected the EZH2, LAMB4, CBL, CUX1, ATM, RB1 and TP53 genes, in addition to JAK2, MPL and CALR. Conclusion: We demonstrated the spectrum of genomic alterations in the groups of the Ukrainian PMF patients with or without the usual mutations in the specific driver genes. We identified several potential genes, which may be involved in the myeloproliferative neoplasms development and their phenotype modification (EZH2, LAMB4, CBL, CUX1, ATM, RB1 and TP53).
- 5 August 2022
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 195 (3) , 453-459
Contribution of BRCA1 5382insC mutation to triplene-gative and luminal types of breast cancer in Ukraine
Purpose The gene BRCA1 plays a key role in DNA repair in breast and ovarian cell lines and this is considered one of target tumor suppressor genes in same line of cancers. The 5382insC mutation is among the most frequently detected in patients (Eastern Europe) with triple-negative breast cancer (TNBC). In Ukraine, there is not enough awareness of necessity to test patients with TNBC for BRCA1 mutations. That is why this group of patients is not well-studied, even through is known the mutation may affect the course of disease. Methods The biological samples of 408 female patients were analyzed of the 5382insC mutation in BRCA1. We compared the frequency of the 5382insC mutation in BRCA1 gene observed in Ukraine with known frequencies in other countries. Results For patients with TNBC, BRCA1 mutations frequency was 11.3%, while in patients with luminal types of breast cancers, the frequency was 2.8%. Prevalence of 5382insC among TNBC patients reported in this study was not different from those in Tunisia, Poland, Russia, and Bulgaria, but was higher than in Australia and Germany. Conclusion The BRCA1 c.5382 mutation rate was recorded for the first time for TNBC patients in a Ukrainian population. The results presented in this study underscore the importance of this genetic testing of mutations in patients with TNBC. Our study supports BRCA1/2 genetic testing for all women diagnosed with TNBC, regardless of the age of onset or family history of cancer and not only for women diagnosed with TNBC at <60y.o., as guidelines recommend.
- 5 August 2022
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 195 (3) , 453-459
Contribution of BRCA1 5382insC mutation to triplene-gative and luminal types of breast cancer in Ukraine
Purpose The gene BRCA1 plays a key role in DNA repair in breast and ovarian cell lines and this is considered one of target tumor suppressor genes in same line of cancers. The 5382insC mutation is among the most frequently detected in patients (Eastern Europe) with triple-negative breast cancer (TNBC). In Ukraine, there is not enough awareness of necessity to test patients with TNBC for BRCA1 mutations. That is why this group of patients is not well-studied, even through is known the mutation may affect the course of disease. Methods The biological samples of 408 female patients were analyzed of the 5382insC mutation in BRCA1. We compared the frequency of the 5382insC mutation in BRCA1 gene observed in Ukraine with known frequencies in other countries. Results For patients with TNBC, BRCA1 mutations frequency was 11.3%, while in patients with luminal types of breast cancers, the frequency was 2.8%. Prevalence of 5382insC among TNBC patients reported in this study was not different from those in Tunisia, Poland, Russia, and Bulgaria, but was higher than in Australia and Germany. Conclusion The BRCA1 c.5382 mutation rate was recorded for the first time for TNBC patients in a Ukrainian population. The results presented in this study underscore the importance of this genetic testing of mutations in patients with TNBC. Our study supports BRCA1/2 genetic testing for all women diagnosed with TNBC, regardless of the age of onset or family history of cancer and not only for women diagnosed with TNBC at <60y.o., as guidelines recommend.
- Open Access
- 10 February 2020
- Published by Bogomolets National Medical University in Ukrainian Scientific Medical Youth Journal
- Vol. 117 (3) , 23-36
ASSOCIATION OF GENOTYPES OF POLYMORPHISMS OF GENES FGFR2, LSP, AND LOC643714 WITH THE RISK OF A POSITIVE MUTATIONAL STATUS OF THE HER-2/NEU GENE IN BREAST CANCER PATIENTS
Breast cancer is the result of genetic and environmental factors that lead to the accumulation of mutations in key regulatory genes. Genetic predisposition to cancer pathologies may be due to mutations in individual genes, such as in BRCA1 and BRCA2, or may be due to a cumulative effect as a result of the interaction of genes of low penetrance. This paper reviews the alleles that determine the risk of high and low penetrance breast cancer and discusses ongoing efforts to identify additional susceptibility genes. The identification of propensity genes is a prerequisite for an individualized assessment of breast cancer risk and a decrease in the incidence of breast cancer. The main goal of this study is to determine the associations of polymorphic variants rs2981582 and rs1219648 of FGFR2, rs3817198 of LSP and rs3803662 of LOC643714 with the risk of breast cancer and the development of a positive mutational status of Her-2/neu. The study group included 300 women diagnosed with breast cancer. Fluorescent in situ hybridization was performed on tumor tissue materials from these patients to determine the amplification status of the Her-2/neu. The distribution of genotypes and alleles was performed by real-time polymerase chain reaction for the following polymorphic variants rs1219648 of FGFR2 (n = 44), rs2981582 of FGFR (n = 99), rs3817198 of LSP1 (n = 75) and rs3803662 of the LOC643714 (n = 82). Among the studied genotypes of polymorphic variants rs3817198 of LSP1, rs3803662 of LOC643714, rs2981582 and rs1219648 of FGFR2, with the inclusion of the risk allele, the association of the propensity to develop breast cancer in women according to the multiplicative model of inheritance (p> 0.05) was not determined. According to the codominant inheritance model, there is an associative relationship with the risk of breast cancer and polymorphism rs3817198 of LSP1, rs3803662 of LOC64371 and rs2981582 of FGFR2 with homozygous genotypes for rare alleles (p <0.05). Women with a positive amplification status of the Her-2/neu, patients with breast cancer, were more likely to carry the risk allele G (OR = 4.80; 95% CI 1.21–28.04, p <0.05) and genotype GG ( OR = 5.82; 95% CI 1.38-16.74, p <0.05) rs3803662 polymorphism of LOC643714, compared with a group of women with negative amplification status of Her-2/neu in patients diagnosed with breast cancer. The results of this study can be useful for searching for additional genetic predictors of breast cancer and a positive mutational status of Her-2/neu.
- 10 February 2020
- Published by Bogomolets National Medical University in Ukrainian Scientific Medical Youth Journal
- Vol. 117 (3) , 23-36
Open AccessASSOCIATION OF GENOTYPES OF POLYMORPHISMS OF GENES FGFR2, LSP, AND LOC643714 WITH THE RISK OF A POSITIVE MUTATIONAL STATUS OF THE HER-2/NEU GENE IN BREAST CANCER PATIENTS
Breast cancer is the result of genetic and environmental factors that lead to the accumulation of mutations in key regulatory genes. Genetic predisposition to cancer pathologies may be due to mutations in individual genes, such as in BRCA1 and BRCA2, or may be due to a cumulative effect as a result of the interaction of genes of low penetrance. This paper reviews the alleles that determine the risk of high and low penetrance breast cancer and discusses ongoing efforts to identify additional susceptibility genes. The identification of propensity genes is a prerequisite for an individualized assessment of breast cancer risk and a decrease in the incidence of breast cancer. The main goal of this study is to determine the associations of polymorphic variants rs2981582 and rs1219648 of FGFR2, rs3817198 of LSP and rs3803662 of LOC643714 with the risk of breast cancer and the development of a positive mutational status of Her-2/neu. The study group included 300 women diagnosed with breast cancer. Fluorescent in situ hybridization was performed on tumor tissue materials from these patients to determine the amplification status of the Her-2/neu. The distribution of genotypes and alleles was performed by real-time polymerase chain reaction for the following polymorphic variants rs1219648 of FGFR2 (n = 44), rs2981582 of FGFR (n = 99), rs3817198 of LSP1 (n = 75) and rs3803662 of the LOC643714 (n = 82). Among the studied genotypes of polymorphic variants rs3817198 of LSP1, rs3803662 of LOC643714, rs2981582 and rs1219648 of FGFR2, with the inclusion of the risk allele, the association of the propensity to develop breast cancer in women according to the multiplicative model of inheritance (p> 0.05) was not determined. According to the codominant inheritance model, there is an associative relationship with the risk of breast cancer and polymorphism rs3817198 of LSP1, rs3803662 of LOC64371 and rs2981582 of FGFR2 with homozygous genotypes for rare alleles (p <0.05). Women with a positive amplification status of the Her-2/neu, patients with breast cancer, were more likely to carry the risk allele G (OR = 4.80; 95% CI 1.21–28.04, p <0.05) and genotype GG ( OR = 5.82; 95% CI 1.38-16.74, p <0.05) rs3803662 polymorphism of LOC643714, compared with a group of women with negative amplification status of Her-2/neu in patients diagnosed with breast cancer. The results of this study can be useful for searching for additional genetic predictors of breast cancer and a positive mutational status of Her-2/neu.
- 1 January 2018
- Published by National Research Center for Radiation Medicine, Hematology and Oncology of the NAMS of Ukraine in Problems of Radiation Medicine and Radiobiology
- Vol. 23, 510-516
EVALUATION OF BURDENSOME SYMPTOMS IN PATIENTS WITH RADIATION/ASSOCIATED AND SPONTANEOUS MYELOPROILIFERATIVE NEOPLASMS WITH THE USE OF OPTIMIZED SELF/ASSESSMENT MPN/SAF TSS
To investigate the intensity of burdensome symptoms using self-assessment MPN-SAF TSS in patientswith radiation-associated and spontaneous myeloproiliferative neoplasms (MPNs). The study included 89 patients with radiation-associated and spontaneous MPNs, the bur-densome symptoms of MPN were determined using MPN-SAF TSS. The average score for complaints in patients with radiation-associated MPNs was significantly higher thanin patients with spontaneous MPNs - 43.46 and 25.04 points, respectively (p = 0.003). MPN patients classified bysubtypes also showed differences regarding intensity of burdensome MPN symptoms, demonstrating significantlyhigher average score of complaints among primary myelofibrosis patients (35.60), compared to polycythemia vera(29.60) and essential thrombocythemia (18.05) patients, (p = 0.005). Our study did not reveal any influence of theJAK2 V617F mutation on MPN burdensome symptoms intensity in MPN patients. We demonstrated a higher intensity of the MPN burdensome symptoms determined by the optimizedself-assessment MPN-SAF TSS in patients with radiation-associated, and in primary myelofibrosis patients, indicat-ing increased severity of patient's general conditions at the stage of diagnosis verification. It is advisable to usethe optimized MPN-SAF TSS at the moment of molecular genetic testing during the diagnosis of MPN for selectionor modifying treatment strategies in order to achieve better quality of life for patients.
- 1 January 2018
- Published by National Research Center for Radiation Medicine, Hematology and Oncology of the NAMS of Ukraine in Problems of Radiation Medicine and Radiobiology
- Vol. 23, 510-516
EVALUATION OF BURDENSOME SYMPTOMS IN PATIENTS WITH RADIATION/ASSOCIATED AND SPONTANEOUS MYELOPROILIFERATIVE NEOPLASMS WITH THE USE OF OPTIMIZED SELF/ASSESSMENT MPN/SAF TSS
To investigate the intensity of burdensome symptoms using self-assessment MPN-SAF TSS in patientswith radiation-associated and spontaneous myeloproiliferative neoplasms (MPNs). The study included 89 patients with radiation-associated and spontaneous MPNs, the bur-densome symptoms of MPN were determined using MPN-SAF TSS. The average score for complaints in patients with radiation-associated MPNs was significantly higher thanin patients with spontaneous MPNs - 43.46 and 25.04 points, respectively (p = 0.003). MPN patients classified bysubtypes also showed differences regarding intensity of burdensome MPN symptoms, demonstrating significantlyhigher average score of complaints among primary myelofibrosis patients (35.60), compared to polycythemia vera(29.60) and essential thrombocythemia (18.05) patients, (p = 0.005). Our study did not reveal any influence of theJAK2 V617F mutation on MPN burdensome symptoms intensity in MPN patients. We demonstrated a higher intensity of the MPN burdensome symptoms determined by the optimizedself-assessment MPN-SAF TSS in patients with radiation-associated, and in primary myelofibrosis patients, indicat-ing increased severity of patient's general conditions at the stage of diagnosis verification. It is advisable to usethe optimized MPN-SAF TSS at the moment of molecular genetic testing during the diagnosis of MPN for selectionor modifying treatment strategies in order to achieve better quality of life for patients.
- Open Access
- 31 October 2017
- Published by Institute of Molecular Biology and Genetics (NAS Ukraine) in Biopolymers and Cell
- Vol. 33 (5) , 393-400
Association of genetic polymorphism with the mutation status of the BRCA1/2 genes in spontanous breast cancer
- 31 October 2017
- Published by Institute of Molecular Biology and Genetics (NAS Ukraine) in Biopolymers and Cell
- Vol. 33 (5) , 393-400
Open AccessAssociation of genetic polymorphism with the mutation status of the BRCA1/2 genes in spontanous breast cancer